Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Fig. 2Fig. 2Fig. 2

Effects of SGLT2 inhibitors on safety outcomes among individuals with diabetic kidney disease. CANVAS indicates Canagliflozin Cardiovascular Assessment Study, CI confidence interval, CREDENCE Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation, eGFR estimated glomerular filtration rate, EMPA‐REG OUTCOME Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients, NR not reported; SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk; SGLT2, sodium-glucose cotransporter 2

Back to article page